Business Context and Reporting Period
This Form 8-K reports on the 2014 Annual Meeting of Stockholders held by Akers Biosciences Inc. on November 4, 2014. The filing details the voting results for director elections, auditor ratification, and executive compensation advisory votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
A quorum was established with greater than 40% of outstanding shares present. The following matters were voted upon:
- Director Elections: Raymond F. Akers, Jr., Ph.D, Thomas Knox, Brandon Knox, and Gavin Moran were elected to one-year terms. All nominees received zero votes against/withheld.
- Auditor Ratification: MorisonCogen, LP was ratified as the independent registered public accountant for 2014.
- Executive Compensation: The non-binding advisory vote on executive compensation was approved.
- Compensation Frequency: Stockholders approved a two-year frequency for future advisory votes on executive compensation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the abstention rates, particularly for Brandon Knox (384,928 abstentions) and the executive compensation vote (462,492 abstentions).
- Confirm the tenure and background of the newly elected directors: Raymond F. Akers, Jr., Thomas Knox, Brandon Knox, and Gavin Moran.
- Review the full proxy statement for details on the executive compensation package that was subject to the advisory vote.
- Check subsequent filings for the company's financial performance for the fiscal year ending 2014, as this 8-K does not contain financial data.